Physician profile
Gregory W Boyd
NPI 1821107939
$19,712.33
in general payments reported to CMS, 2019-2025
61 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,630 · 2020: $2,780 · 2021: $4,008 · 2022: $2,462 · 2023: $2,862 · 2024: $1,653 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,833.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,668.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,009.66 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,672.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,348.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,135.60 | 2019-2025 | |
| Amarin Pharma, INC. | $1,124.32 | 2019-2022 | |
| Amgen INC. | $987.01 | 2019-2024 | Repatha, Otezla, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $942.57 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $735.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $624.85 | 2019-2022 | |
| Abbott Laboratories | $554.87 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $454.84 | 2021-2024 | |
| Antares Pharma, INC. | $411.15 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $382.12 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $360.67 | 2019-2023 | Xarelto |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.